EdgarLookup

NVIDIA CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that NVIDIA CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
55.6%
Profit Margin
Net income ÷ revenue
58.1%
Return on Assets
Net income ÷ assets
0.31x
Debt-to-Equity
Total liabilities ÷ equity
+65.5%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $215.94B Feb 25, 2026
FY2026 Jan 26, 2025 $130.50B Feb 25, 2026
FY2026 Jan 28, 2024 $60.92B Feb 25, 2026
FY2025 Jan 29, 2023 $26.97B Feb 26, 2025
FY2024 Jan 30, 2022 $26.91B Feb 21, 2024
FY2023 Jan 31, 2021 $16.68B Feb 24, 2023
FY2022 Jan 26, 2020 $10.92B Mar 18, 2022
FY2018 Jan 28, 2018 $2.91B Feb 28, 2018
FY2018 Oct 29, 2017 $2.64B Feb 28, 2018
FY2018 Jul 30, 2017 $2.23B Feb 28, 2018

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2022 Jan 30, 2022 $26.91B Mar 18, 2022
FY2022 Jan 31, 2021 $16.68B Mar 18, 2022
FY2020 Jan 26, 2020 $3.11B Feb 20, 2020
FY2020 Oct 27, 2019 $3.01B Feb 20, 2020
FY2020 Jul 28, 2019 $2.58B Feb 20, 2020
FY2020 Apr 28, 2019 $2.22B Feb 20, 2020
FY2020 Jan 27, 2019 $2.21B Feb 20, 2020
FY2020 Oct 28, 2018 $3.18B Feb 20, 2020
FY2020 Jul 29, 2018 $3.12B Feb 20, 2020
FY2020 Apr 29, 2018 $3.21B Feb 20, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $153.46B Feb 25, 2026
FY2026 Jan 26, 2025 $97.86B Feb 25, 2026
FY2026 Jan 28, 2024 $44.30B Feb 25, 2026
FY2025 Jan 29, 2023 $15.36B Feb 26, 2025
FY2024 Jan 30, 2022 $17.48B Feb 21, 2024
FY2023 Jan 31, 2021 $10.40B Feb 24, 2023
FY2020 Jan 26, 2020 $2.02B Feb 20, 2020
FY2020 Oct 27, 2019 $1.92B Feb 20, 2020
FY2020 Jul 28, 2019 $1.54B Feb 20, 2020
FY2020 Apr 28, 2019 $1.30B Feb 20, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $120.07B Feb 25, 2026
FY2026 Jan 26, 2025 $72.88B Feb 25, 2026
FY2026 Jan 28, 2024 $29.76B Feb 25, 2026
FY2025 Jan 29, 2023 $4.37B Feb 26, 2025
FY2024 Jan 30, 2022 $9.75B Feb 21, 2024
FY2023 Jan 31, 2021 $4.33B Feb 24, 2023
FY2020 Jan 26, 2020 $950.00M Feb 20, 2020
FY2020 Oct 27, 2019 $899.00M Feb 20, 2020
FY2020 Jul 28, 2019 $552.00M Feb 20, 2020
FY2020 Apr 28, 2019 $394.00M Feb 20, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $130.39B Feb 25, 2026
FY2026 Jan 26, 2025 $81.45B Feb 25, 2026
FY2026 Jan 28, 2024 $32.97B Feb 25, 2026
FY2025 Jan 29, 2023 $4.22B Feb 26, 2025
FY2024 Jan 30, 2022 $10.04B Feb 21, 2024
FY2023 Jan 31, 2021 $4.53B Feb 24, 2023
FY2022 Jan 26, 2020 $2.85B Mar 18, 2022
FY2021 Jan 27, 2019 $3.80B Feb 26, 2021
FY2020 Jan 28, 2018 $3.21B Feb 20, 2020
FY2019 Jan 29, 2017 $1.93B Feb 21, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $18.50B Feb 25, 2026
FY2026 Jan 26, 2025 $12.91B Feb 25, 2026
FY2026 Jan 28, 2024 $8.68B Feb 25, 2026
FY2025 Jan 29, 2023 $7.34B Feb 26, 2025
FY2024 Jan 30, 2022 $5.27B Feb 21, 2024
FY2023 Jan 31, 2021 $3.92B Feb 24, 2023
FY2022 Jan 26, 2020 $2.83B Mar 18, 2022
FY2021 Jan 27, 2019 $2.38B Feb 26, 2021
FY2020 Jan 28, 2018 $1.80B Feb 20, 2020
FY2019 Jan 29, 2017 $1.46B Feb 21, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $4.58B Feb 25, 2026
FY2026 Jan 26, 2025 $3.49B Feb 25, 2026
FY2026 Jan 28, 2024 $2.65B Feb 25, 2026
FY2025 Jan 29, 2023 $2.44B Feb 26, 2025
FY2024 Jan 30, 2022 $2.17B Feb 21, 2024
FY2023 Jan 31, 2021 $1.94B Feb 24, 2023
FY2022 Jan 26, 2020 $1.09B Mar 18, 2022
FY2021 Jan 27, 2019 $991.00M Feb 26, 2021
FY2020 Jan 28, 2018 $815.00M Feb 20, 2020
FY2019 Jan 29, 2017 $663.00M Feb 21, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $102.72B Feb 25, 2026
FY2026 Jan 26, 2025 $64.09B Feb 25, 2026
FY2026 Jan 28, 2024 $28.09B Feb 25, 2026
FY2025 Jan 29, 2023 $5.64B Feb 26, 2025
FY2024 Jan 30, 2022 $9.11B Feb 21, 2024
FY2023 Jan 31, 2021 $5.82B Feb 24, 2023
FY2022 Jan 26, 2020 $4.76B Mar 18, 2022
FY2021 Jan 27, 2019 $3.74B Feb 26, 2021
FY2020 Jan 28, 2018 $3.50B Feb 20, 2020
FY2019 Jan 29, 2017 $1.67B Feb 21, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2011 Jan 29, 2012 $138.74M Mar 13, 2012
FY2011 Jan 30, 2011 $97.89M Mar 13, 2012
FY2011 Jan 31, 2010 $77.60M Mar 13, 2012

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $206.80B Feb 25, 2026
FY2026 Jan 26, 2025 $111.60B Feb 25, 2026
FY2025 Jan 28, 2024 $65.73B Feb 26, 2025
FY2024 Jan 29, 2023 $41.18B Feb 21, 2024
FY2023 Jan 30, 2022 $44.19B Feb 24, 2023
FY2022 Jan 31, 2021 $28.79B Mar 18, 2022
FY2021 Jan 26, 2020 $17.32B Feb 26, 2021
FY2020 Jan 27, 2019 $13.29B Feb 20, 2020
FY2019 Jan 28, 2018 $11.24B Feb 21, 2019
FY2018 Jan 29, 2017 $9.84B Feb 28, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $49.51B Feb 25, 2026
FY2026 Jan 26, 2025 $32.27B Feb 25, 2026
FY2025 Jan 28, 2024 $22.75B Feb 26, 2025
FY2024 Jan 29, 2023 $19.08B Feb 21, 2024
FY2023 Jan 30, 2022 $17.58B Feb 24, 2023
FY2022 Jan 31, 2021 $11.90B Mar 18, 2022
FY2021 Jan 26, 2020 $5.11B Feb 26, 2021
FY2020 Jan 27, 2019 $3.95B Feb 20, 2020
FY2019 Jan 28, 2018 $3.77B Feb 21, 2019
FY2018 Jan 29, 2017 $4.05B Feb 28, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $157.29B Feb 25, 2026
FY2026 Jan 26, 2025 $79.33B Feb 25, 2026
FY2026 Jan 28, 2024 $42.98B Feb 25, 2026
FY2026 Jan 29, 2023 $22.10B Feb 25, 2026
FY2025 Jan 30, 2022 $26.61B Feb 26, 2025
FY2024 Jan 31, 2021 $16.89B Feb 21, 2024
FY2023 Jan 26, 2020 $12.20B Feb 24, 2023
FY2022 Jan 27, 2019 $9.34B Mar 18, 2022
FY2021 Jan 28, 2018 $7.47B Feb 26, 2021
FY2020 Jan 29, 2017 $5.76B Feb 20, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $20.83B Feb 25, 2026
FY2026 Jan 26, 2025 $5.19B Feb 25, 2026
FY2025 Jan 28, 2024 $4.43B Feb 26, 2025
FY2024 Jan 29, 2023 $4.37B Feb 21, 2024
FY2023 Jan 30, 2022 $4.35B Feb 24, 2023
FY2022 Jan 31, 2021 $4.19B Mar 18, 2022
FY2021 Jan 26, 2020 $618.00M Feb 26, 2021
FY2020 Jan 27, 2019 $618.00M Feb 20, 2020
FY2019 Jan 28, 2018 $618.00M Feb 21, 2019
FY2018 Jan 29, 2017 $618.00M Feb 28, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $146.97B Feb 25, 2026
FY2026 Jan 26, 2025 $68.04B Feb 25, 2026
FY2025 Jan 28, 2024 $29.82B Feb 26, 2025
FY2024 Jan 29, 2023 $10.17B Feb 21, 2024
FY2023 Jan 30, 2022 $16.24B Feb 24, 2023
FY2022 Jan 31, 2021 $18.91B Mar 18, 2022
FY2021 Jan 26, 2020 $14.97B Feb 26, 2021
FY2020 Jan 27, 2019 $12.57B Feb 20, 2020
FY2019 Jan 28, 2018 $8.79B Feb 21, 2019
FY2018 Jan 29, 2017 $6.11B Feb 28, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $10.61B Feb 25, 2026
FY2026 Jan 26, 2025 $8.59B Feb 25, 2026
FY2025 Jan 28, 2024 $7.28B Feb 26, 2025
FY2024 Jan 29, 2023 $3.39B Feb 21, 2024
FY2023 Jan 30, 2022 $1.99B Feb 24, 2023
FY2022 Jan 31, 2021 $847.00M Mar 18, 2022
FY2021 Jan 26, 2020 $10.90B Feb 26, 2021
FY2020 Jan 27, 2019 $782.00M Feb 20, 2020
FY2019 Jan 28, 2018 $4.00B Feb 21, 2019
FY2019 Jan 29, 2017 $1.77B Feb 21, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 $8.47B Feb 25, 2026
FY2026 Jan 26, 2025 $8.46B Feb 25, 2026
FY2025 Jan 28, 2024 $9.71B Feb 26, 2025
FY2024 Jan 29, 2023 $10.95B Feb 21, 2024
FY2023 Jan 30, 2022 $10.95B Feb 24, 2023
FY2022 Jan 31, 2021 $6.96B Mar 18, 2022
FY2021 Jan 26, 2020 $1.99B Feb 26, 2021
FY2020 Jan 27, 2019 $1.99B Feb 20, 2020
FY2019 Jan 28, 2018 $1.99B Feb 21, 2019
FY2018 Jan 29, 2017 $1.98B Feb 28, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 4 Feb 25, 2026
FY2026 Jan 26, 2025 2 Feb 25, 2026
FY2026 Jan 28, 2024 1 Feb 25, 2026
FY2025 Jan 29, 2023 0 Feb 26, 2025
FY2024 Jan 30, 2022 3 Feb 21, 2024
FY2023 Jan 31, 2021 1 Feb 24, 2023
FY2020 Jan 26, 2020 1 Feb 20, 2020
FY2020 Oct 27, 2019 1 Feb 20, 2020
FY2020 Jul 28, 2019 0 Feb 20, 2020
FY2020 Apr 28, 2019 0 Feb 20, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 4 Feb 25, 2026
FY2026 Jan 26, 2025 2 Feb 25, 2026
FY2026 Jan 28, 2024 1 Feb 25, 2026
FY2025 Jan 29, 2023 0 Feb 26, 2025
FY2024 Jan 30, 2022 3 Feb 21, 2024
FY2023 Jan 31, 2021 1 Feb 24, 2023
FY2020 Jan 26, 2020 1 Feb 20, 2020
FY2020 Oct 27, 2019 1 Feb 20, 2020
FY2020 Jul 28, 2019 0 Feb 20, 2020
FY2020 Apr 28, 2019 0 Feb 20, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2026 Jan 25, 2026 24.30B Feb 25, 2026
FY2026 Jan 26, 2025 24.48B Feb 25, 2026
FY2025 Jan 28, 2024 24.64B Feb 26, 2025
FY2024 Jan 29, 2023 2.47B Feb 21, 2024
FY2023 Jan 30, 2022 2.51B Feb 24, 2023
FY2022 Jan 31, 2021 2.48B Mar 18, 2022
FY2021 Jan 26, 2020 612.00M Feb 26, 2021
FY2020 Jan 27, 2019 606.00M Feb 20, 2020
FY2019 Jan 28, 2018 606.00M Feb 21, 2019
FY2018 Jan 29, 2017 585.00M Feb 28, 2018